CN1626669A - 完全人源化抗体的制备 - Google Patents

完全人源化抗体的制备 Download PDF

Info

Publication number
CN1626669A
CN1626669A CNA2004100684394A CN200410068439A CN1626669A CN 1626669 A CN1626669 A CN 1626669A CN A2004100684394 A CNA2004100684394 A CN A2004100684394A CN 200410068439 A CN200410068439 A CN 200410068439A CN 1626669 A CN1626669 A CN 1626669A
Authority
CN
China
Prior art keywords
antibody
antigen
cell
cells
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100684394A
Other languages
English (en)
Chinese (zh)
Inventor
金立德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCL Holdings Co Ltd
Original Assignee
CCL Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CCL Holdings Co Ltd filed Critical CCL Holdings Co Ltd
Publication of CN1626669A publication Critical patent/CN1626669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004100684394A 2003-07-16 2004-07-15 完全人源化抗体的制备 Pending CN1626669A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/622003 2003-07-16
US10/622,003 US20050014230A1 (en) 2003-07-16 2003-07-16 Preparation of fully human antibodies

Publications (1)

Publication Number Publication Date
CN1626669A true CN1626669A (zh) 2005-06-15

Family

ID=33477124

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100684394A Pending CN1626669A (zh) 2003-07-16 2004-07-15 完全人源化抗体的制备

Country Status (4)

Country Link
US (2) US20050014230A1 (enExample)
EP (1) EP1498426A1 (enExample)
JP (1) JP2005034154A (enExample)
CN (1) CN1626669A (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212133A (zh) * 2011-03-30 2011-10-12 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN103755805A (zh) * 2014-02-11 2014-04-30 中国疾病预防控制中心病毒病预防控制所 HIV-1Env特异性的全人单克隆抗体
CN109157690A (zh) * 2018-06-15 2019-01-08 翁炳焕 猴-人细胞融合母胎血型不合治疗杂交株的制备
CN110799840A (zh) * 2016-10-23 2020-02-14 伯克利之光生命科技公司 筛选b细胞淋巴细胞的方法
CN119591699A (zh) * 2019-05-21 2025-03-11 吉利德科学公司 鉴定对采用gp120 v3聚糖导向的抗体的疗法敏感的hiv患者的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492871C2 (ru) 2008-08-01 2013-09-20 АКСИС, Инс. Терапевтическое или профилактическое средство для лечения остеоартрита
CA2788527A1 (en) 2010-01-29 2011-08-04 Axis Inc. Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
KR101684246B1 (ko) 2010-01-29 2016-12-08 가부시키가이샤 아크시스 변형성 관절증 치료제를 포함하는 주사제
FR2998579B1 (fr) 2012-11-27 2015-06-19 Commissariat Energie Atomique Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
EP4137519A1 (en) 2013-08-09 2023-02-22 The Trustees Of The University Of Pennsylvania Fusion protein comprising ifn-gamma and anti-erbb antibody for the treatment of cancers
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US6309880B1 (en) * 1989-04-25 2001-10-30 Tanox, Inc. Antibodies specific for CD4-binding domain of HIV-1
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
KR100337069B1 (ko) * 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
US6261558B1 (en) * 1993-10-19 2001-07-17 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6391635B1 (en) * 1997-11-24 2002-05-21 Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO2001000678A1 (en) * 1999-06-30 2001-01-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212133A (zh) * 2011-03-30 2011-10-12 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN103755805A (zh) * 2014-02-11 2014-04-30 中国疾病预防控制中心病毒病预防控制所 HIV-1Env特异性的全人单克隆抗体
CN110799840A (zh) * 2016-10-23 2020-02-14 伯克利之光生命科技公司 筛选b细胞淋巴细胞的方法
CN109157690A (zh) * 2018-06-15 2019-01-08 翁炳焕 猴-人细胞融合母胎血型不合治疗杂交株的制备
CN119591699A (zh) * 2019-05-21 2025-03-11 吉利德科学公司 鉴定对采用gp120 v3聚糖导向的抗体的疗法敏感的hiv患者的方法

Also Published As

Publication number Publication date
US20080248531A1 (en) 2008-10-09
JP2005034154A (ja) 2005-02-10
EP1498426A1 (en) 2005-01-19
US20050014230A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
CN1207306C (zh) 用于预防和治疗hiv感染和免疫疾病的肽组合物
CN1230444C (zh) 含有hiv细胞毒t淋巴细胞表位的hiv多肽或肽或其多聚核苷酸表达构建体的用途
CN1267452C (zh) 单克隆抗体、抗原和恶性疾病的诊断和治疗
CN1221566C (zh) 结合gClq受体的HIV－lgp120相关肽及其编码寡核苷酸
CN1492040A (zh) 单克隆人天然抗体
CN1533284A (zh) 生物活性 H I V － 1 T a t、其片段或衍生物用于预防或治疗性免疫接种和/或治疗其它疾病中靶向和/或激活抗原呈递细胞、和/或运送货物分子的用途
CN1283121A (zh) 用于预防和治疗接种的hiv－1tat或其衍生物
CN1067382A (zh) 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
CN1626669A (zh) 完全人源化抗体的制备
CN1651457A (zh) Hiv－1 o组(或亚组)逆转录病毒抗原的核苷酸序列
CN1630663A (zh) 结合蛋白磷酸酶2a的合成的或者天然的肽,其鉴定方法以及用途
CN1526072A (zh) 埃-巴二氏病毒(ebv)肿瘤相关潜伏膜蛋白的胞外结构域的鉴定方法和与之反应的抗体试剂的选择方法
CN1345775A (zh) 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
CN1079166A (zh) 用白细胞介素-10抑制移植物抗宿主病
CN1227610A (zh) 抗cd4和趋化因子受体结构域复合物的抗体及其抵抗hiv感染的应用
CN1081716A (zh) 用于预防和治疗hiv感染的重组人hiv-中和性单克隆抗体
CN1926153A (zh) 治疗msrv/herv－w相关病理学的组合物
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN1308546A (zh) 疫苗
CN1657102A (zh) 基于表位的SARS－Cov基因疫苗及其构建
CN1809381A (zh) 具有稀有二硫化物结构的hiv－1包膜糖蛋白
CN1930184A (zh) 新型tat复合物，及包含其的疫苗
CN101057975A (zh) 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用
CN1236818C (zh) 山羊关节炎－脑炎病毒提供抗hiv－1感染的免疫保护
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication